In patients after cardiac arrest in therapeutic hypothermia the nonresponder rate is extremely high. Comparing prasugrel and ticagrelor with clopidogrel, both "new" antiplatelet drugs can ameliorate platelet inhibition significantly, but still show high rates of non-responders. It is suggestive that improved platelet inhibition results in better clinical outcome. Large clinical studies have to test this hypothesis also in hypothermia. Background: Prasugrel inhibits ADP-induced platelet aggregation to a greater extent than do standard dose clopidogrel. However, there has been little data comparing the platelet inhibitory efficacy between low dose prasugrel (5 mg) and standard dose clopidogrel (75 mg). Methods: Forty three patients who underwent percutaneous coronary stent implantation at least one year ago were prospectively randomized to clopidogrel 75 mg (group I, n=23) and prasugrel 5 mg (group II, n=20) with aspirin 100 mg for the following 28 days. Another 20 patients were allocated to prasugrel 10 mg (group III) as reference comparison group. All patients, who weighed ≥60 kg and were <75 years old, had been receiving daily aspirin 100 mg and clopidogrel 75 mg at the time of randomization. Platelet function test was performed at baseline and 28 days after randomization using VerifyNow P2Y12 point-of-care assay. The primary endpoint was P2Y12 reaction unit (PRU) at 28 days between group I and group II. Results: There were no differences in baseline PRU values between three groups. Group II had significantly lower PRU value compared with group I (174.6±60.2 vs. 223.4±72.9, p = 0.022) at 28 days, while group III showed lower PRU value (81.7±42.5) compared with group II (p<0.001). Group II demonstrated higher percent change of PRUs, defined as the relative difference of PRUs at baseline and 28 days, compared with group I (18.7±20.9 vs. -1.2±18.9, p=0.04). The rate of high on-treatment platelet reactivity (PRU ≥235) was significant lower in group II than group I (15.0% vs. 56.5%, p=0.010).
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Rationale: Heparin-induced thrombocytopenia (HIT) is a drug-induced, immunemediated type of thrombocytopenia. Its incidence is continuously increasing. HIT poses a tremendous surgical challenge, specifically in cardiothoracic surgery where heparin is the only anticoagulant drug that can be used during cardiopulmonary bypass (CPB) with the possibility of antagonization at the end of surgery. Anticoagulants that are approved for treatment of HIT (lepirudin, argatroban, danaparoid, bivalirudin) are not approved for CPB, and may pose great bleeding risks due to their lack of antagonization. Based on the antibody-mediated nature of the disease, we reasoned that it may be possible to eliminate HIT antibodies by plasmaphereses preoperatively, allowing heparin and protamin to be used during the main surgical procedure. Objective: We here report our first experience with plasmaphereses in 8 HIT II-positive patients undergoing major cardiothoracic surgery using heparin/protamin. Methods: The Patients received the following operative procedures: hearttransplantation (n=4), lung-transplantation (n=1), heart-lung-transplantation (n=1) and elective aortic valve replacement (n=2). HIT II was confirmed in all 8 patients and anticoagulant treatment was performed with argatroban until the time of surgery (or until the beginning of plasmaphereses). The transplant patients received a single run of plasmaphereses immediately after the donor organ was accepted and before transplantation. The patients requiring aortic valve replacement received two or three episodes of plasmaphereses and postprocedural verification that HIT antibodies had been fully eliminated. The surgical procedures were then performed using standard heparin/protamin. Postopoerative anticoagulation was again conducted with argatroban. Results: All patients survived the operation and are still alive. There were no complications or side effects during the plasma exchange. The use of heparin during the transplantation or valve replacement was free of complications. No thromboembolic or bleeding complications were observed.
Conclusions:
The results suggest that preoperative plasma exchange to eliminate circulating anti-heparin antibodies in HIT-II positive patients and using heparin during a major cardiothoracic procedure is safe. The technique may allow a safer and technically easier treatment of a continuously growing group of patients, specifically transplant patients. However, more experience is needed to verify this suggestion.
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Stent thrombosis after primary angioplasty -incidence, timing and long term prognostic: 5 year follow-up registry Objective: This study sought to assess long term incidence, timing and prognostic of stent thrombosis (ST) after drug-eluting stent (DES) or bare-metal stent (BMS) implantation in patients undergoing primary percutaneous coronary intervention (PPCI). Background: Although DES remarkably reduced the incidence of stentrestenosis and the need for target lesion revascularization (TLR) compared to BMS, its widespread use has raised concerns regarding the occurrence of very late ST (>1 year). The incidence and timing of ST remain unsettled, with consequent uncertainty about risk stratification and long-term recommendations for antiplatelet medications. Methods: From 2001 to 2007 consecutive patients undergoing PPCI single tertiary-care center were included and prospectively followed up for at least 5 years. We analyzed ST occurrence as defined by the Academic Research Consortium (ARC) and also assessed the cumulative incidence of major adverse cardiac events (MACE) defined as death, reinfarction or TLR at 5-year follow up. Results: There were 1156 STEMI patients undergoing PPCI in study period. Patients not receiving a stent (92, 7.9%) were excluded from the analysis. Forty patients (3.8%) were lost to follow up. Mean follow up time was 64.3 months. DES was used in 417 (39.2%). Patients receiving DES were more likely to be younger (61±10 vs 69±11, p=0.03) and have single vessel disease (56 vs 48%, p= 0.02). No other baseline characteristics were found to differ between the 2 groups (Diabetes 18.3%, Severe LV dysfunction 10.2%). Five-year definite ST was found in 6 patients (1.44%) in the DES group and in 4 (0.75%) in BMS group. Considering definite or probable ST the total events number raised to 11 (2.6%) in the DES group and to 22 (4.1%) in BMS group. There was also no difference in the timing of ST (very late ST for BMS 1.1% vs 1.4% for DES, p=ns). Interestingly, ST was associated with an increase in 5-year MACE as compared to pts with reinfarction not due to ST (33 vs 19.8%, p=ns). This was not driven by a mortality difference. Conclusion: Stent thrombosis is an infrequent event (3,38%) after PPCI at 5-year follow up. DES use in this setting was not associated with an increases risk of ST. Although ST is linked with dismal prognosis, this does not seem to be worse than a reinfartion unrelated to ST. High MPV has been recently considered as an independent risk factor for poor outcomes after ST-segment elevation myocardial infarction (STEMI). Methods: We analyzed 128 patients diagnosed with first STEMI successfully reperfused during three consecutive years. MPV was measured on admission and a cardiac magnetic resonance (CMR) exam was performed within the first week in all patients. Myocardial necrosis size was estimated by the area of late gadolinium enhancement (LGE), identifying microvascular obstruction (MVO) if present. Clinical outcomes were recorded at one year follow-up. High MPV was defined as a value in the third tertile (≥ 9.5 fL), and a low MPV, as a value in the lower two. Results: We found a slight but significant correlation between MPV and infarct size (r=0.287, p=0.008). Patients with high MPV had more extensive infarcted area (percentage of necrosis by LGE: 17.6 vs 12.5%, p=0.021) and more presence of MVO (patients with MVO pattern: 44.4 vs 25.3%, p=0.027). In a multivariable analysis, HR for MACE was 3.35 (95% CI 1.1-9.9, p 0.03) in patients with high MPV (Table) . 
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Methods and results:
We studied 240 patients with previous VTE and 240 controls. Presence of MetS was identified according to NCEP ATP III guidelines and flow cytometry was used to quantify circulating CD34+ cells. VTE patients showed higher BMI, waist circumference, triglycerides levels, blood glucose, hs-CRP and lower HDL cholesterol levels. The prevalence of MetS was significantly higher in VTE (38,3%) than in control individuals (21,3%) with an adjusted odd ratio for VTE of 1,96 (p=0.002). VTE patients had higher circulating neutrophils (p<0.0001), while the CD34+ cell count was significantly lower among patients with unprovoked VTE compared to both provoked VTE (p=0.004) and controls (p=0.003). Subjects were also grouped according to presence/absence of MetS (MetS+ or MetS -) and the level (high/low) of both CD34+ cells and neutrophils. Very high adjusted odd ratios for VTE were observed among neutrophils_high/Met+ (OR 3.58, p<0.0001) and CD34+_low/MetS+ (OR 3.98, p<0.0001) subjects as compared to the neutrophils_low/MetS-and CD34+_high/MetS-groups respectively. Conclusions: Low CD34+ blood cell count and high circulating neutrophils interplay with MetS in raising the risk for venous thromboembolic events. Background and objectives: Clopidogrel low-response (CLR) has been linked to adverse clinical events and individualization of antiplatelet therapy according to platelet function monitoring has become possible. We aimed at investigating the antiplatelet effect and safety of standard-dose prasugrel compared to doubledose clopidogrel in patients presenting with stable coronary disease or acute coronary syndromes and exhibiting high on-treatment platelet reactivity (HTPR) at baseline. Methods: Platelet reactivity was assessed with multiple electrode aggregometry (MEA) in patients with ischemic heart disease undergoing cardiac catheterization. The cut-off for response to clopidogrel was set to 70 Multiplate-ADP Units with low-response defined as MEA-values>70 U. Of the 923 screened, 237 (25.7%) exhibited CLR and 106 patients were randomized to an intensified antiplatelet regimen for one month: 52 were assigned to double-maintenance dose clopidogrel and 54 were assigned to standard dose prasugrel. The remaining 131 patients with HTPR were excluded mainly due to contraints to prasugrel use and served instead as controls.
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Results: HTPR was less pronounced in stable angina patients. The prevalence of diabetes was greater in the clopidogrel low-response population compared to patients with normal platelet reactivity. (30.8% vs 23.9%, p=0.039) Intensifying antiplatelet therapy improved platelet inhibition in 73.1% of all randomized patients. Prasugrel entailed a much greater platelet inhibition (54U ±24 versus 61U ±24 for clopidogrel, p=0.02) and a lower rate of poor response at follow-up compared to double maintenance-dose clopidogrel (20.4% of HTPR in the prasugrel-versus 42% in the clopidogrel arm, p=0.02). No major bleeds were observed during follow-up. In the control group with no intervention (n=131), we observed 3 cases of cardiovascular deaths within 30 days following the index procedure, while no case of fatal outcome was reported in the randomized group. Conclusion: Tailored antiplatelet therapy in patients exhibiting Clopidogrel lowresponse prior to percutaneous coronary intervention proved to efficiently reduce platelet activity. Prasugrel demonstrated a greater reduction in platelet aggregation compared to double-dose clopidogrel and also a greater reduction in the rate of HTPR at follow-up. Both regimens were well tolerated and no cases of adverse clinical events were reported in the randomized group.
